Cardiosense

CardioTag™ is the world's first noninvasive device delivering PCWP at point-of-care, enabling clinicians to precisely manage Heart Failure patients.

Latest funding

$15M Series A · December 13, 2022

Latest round on record: Series A, January 2026, amount undisclosed.

Website: cardiosense.com.

X: @CardiosenseInc · 162 followers.

LinkedIn: cardiosense.

Categories: Health and bio Data and analytics Education.

Sectors: Artificial Intelligence (AI), Health Care, Health Diagnostics, Machine Learning, Predictive Analytics.

Stage: Series A.

Based in: Chicago, United States.

Last round: Jan 9, 2026 · 310 days ago.

On Recent Funding since: Sep 29, 2026.

Signals

X account@CardiosenseInc · created Jun 7, 2021 (5 years old) · 162 followers

Website registeredFeb 28, 2000 (26 years old)

About Cardiosense

FDA-cleared Class II.

TIMELINE · MONEY RAISED

@CardiosenseInc·Raised $15M in 1 sourced round·1 signal before the first raise

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Date	Round	Amount	Lead	Source
Jan 9, 2026	Series A	undisclosed	—	fundraisingfox.com
Dec 13, 2022	Series A	$15M	BBroadview Ventures	Fierce Biotech

AG
Amit Gupta Co-founder, Advisor

source: cardiosense.com
AC
Andrew Carek Co-founder, Chief Technical Officer

source: cardiosense.com
ME
Mozziyar Etemadi Co-founder, Head of AI

source: cardiosense.com
OI
Omer Inan Co-founder, Chief Scientific Officer

source: cardiosense.com
EM
Eric Meizlish Chief Executive Officer
JM
John Martin Executive Vice President and Chief Medical Officer
LN
Luke Neill VP, Clinical Affairs

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/cardiosense (get a free API key).